The Dow Rebounds on Pharma, DuPont Strength, but Will the Gains Last?

Before you go, we thought you'd like these...
Before you go close icon

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.

After yesterday's drop of more than 325 points for the Dow Jones Industrials , investors were ready for a respite, and today's 72-point gain gave them at least some comfort from what has been a terrible beginning to the year. Yet even though pharma giants Merck and Pfizer joined chemical company DuPont in leading the Dow higher Tuesday, it's far from clear whether the Dow has actually finished its downward move to begin 2014.

Strength from pharmaceutical stocks Pfizer and Merck, both of which rose 2.75% today, has come from a number of corners. First, declining bond yields have helped support their share prices, as many investors look at their relatively low growth and high dividend yields as making the stocks more like bond substitutes than legitimate growth candidates.

Yet the two companies also have opportunities to streamline their operations. Merck earned an upgrade from analysts at SunTrust today, who argued that the combination of cost cutting, more favorable drug development, and smart internal corporate restructuring efforts could boost shares in the near future. Analysts at Jefferies cited nearly exactly the same factors in upgrading Pfizer, also including the anticipated fast-track approval process and launch of the company's palbociclib breast-cancer treatment by the end of the year.

Meanwhile, DuPont gained 2.7% despite the resignation of chief marketing and sales officer Scott Coleman this morning. There's no obvious reason to think that Coleman's departure was linked to DuPont's evolving strategy to emphasize its agricultural sector over its traditional chemicals business, but aligning top executives to move the company forward in the direction of higher margins will be critical for the company's future success. DuPont's restructuring strategy has plenty of potential to bring profit growth, but it will take time for the company to realize that full potential.

Long-term investors shouldn't get bogged down in whether today's smaller gains compared to yesterday's bigger losses imply that further declines are likely. Finding an investment strategy that works regardless of whether stocks move up or down in the next day or week is essential to keep yourself from becoming an emotional wreck in the wake of rising volatility.

Be smart about your stock market strategy
It's no secret that investors tend to be impatient with the market, but the best investment strategy is to buy shares in solid businesses and keep them for the long term. In the special free report "3 Stocks That Will Help You Retire Rich," The Motley Fool shares investment ideas and strategies that could help you build wealth for years to come. Click here to grab your free copy today.

The article The Dow Rebounds on Pharma, DuPont Strength, but Will the Gains Last? originally appeared on

Dan Caplinger and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading